1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Merck & Co Inc

For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of its mission to save and improve lives. It demonstrates its commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals - including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases - as we aspire to be the premier research-intensive biopharmaceutical company in the world.
Kenneth Frazier

2000 Galloping Hill Rd
Kenilworth, New Jersey 07033-1310
Phone: 19087404000


Merck Q1 Earnings Preview: Strong quarter expectations on the back of core products'' growth
Apr 24, 2024 14:03pm

No summary available.

Source:Seeking Alpha
Hanmi, Merck Collaborate To Evaluate BH3120 + Keytruda Combination In Metastatic Solid Tumors
Apr 24, 2024 02:30am

KENILWORTH (NJ) (dpa-AFX) - Korea''s Hanmi Pharmaceutical said it has entered into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc. (MRK).As per the agreement, Hanmi Pharm…

Source:Finanz Nachrichten
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab)
Apr 24, 2024 01:27am

Hanmi Pharmaceutical announces Clinical Trial Collaboration with MSD to evaluate ''BH3120'' in combination with KEYTRUDA in phase 1 clinical trial in patients with progressive or metastatic solid tumors SEOUL, South Korea , April 24, 2024 /PRNewswire/ -- Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park ), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and Supply Agreement (CTCSA) with MSD (a tradename of Merck & Co., Inc., Rahway, NJ , USA). Upon the execution of the agreement, Hanmi Pharmaceutical will conduct a phase 1 clinical trial to evaluate the safety and efficacy of its immuno-oncology drug, ''BH3120'', in combination with MSD''s anti-PD-1 therapy, KEYTRUDA ® (pembrolizumab), in patients with progressive or metastatic solid tumors. Hanmi Pharmaceutical will sponsor the clinical trial, and MSD will supply KEYTRUDA. ''BH3120'' is a next-generation immunotherapy drug that applies ''Pentambody'', a bispecific antibody platform technology, currently under joint development by Hanmi Pharmaceutical and its Chinese subsidiary, BJHM (Beijing Hanmi Pharmaceutical).

Source:PR Newswire Asia (English)
Investor Alert: Prepare for the Market Crash With These 3 Stocks
Apr 23, 2024 21:11pm

As an investor with significant positions in equities, I am an optimist. However, it’s important to be realistic at the same time. This helps in readjusting the portfolio depending on macroeconomic, geopolitical, and other headwinds. In my view, potential delay in rate cuts is likely to make the market nervous as it might imply a hard landing for the economy. I would therefore look at stocks to buy for a market crash. I must however add that I see the first-rate cut coming before the Presidential elections. Therefore, there are two strategies that I would consider for the coming quarters. First, buy low-beta blue-chip stocks that would protect the portfolio from capital erosion if there is a 10% to 15% correction in the index. Further, look at buying quality growth stocks if the broad markets indeed decline in the coming months. I expect a strong recovery in the markets towards the end of the year. For now, let’s discuss three stocks to buy for a market crash. Newmont Corporation (NEM) Source: Piotr Swat/Shutterstock Gold has declined from highs with tensions deescalating in the Middle East.

Exploring Analyst Estimates for Merck Q1 Earnings, Beyond Revenue and EPS
Apr 23, 2024 18:20pm

Wall Street analysts forecast that Merck (NYSE: MRK ) will report quarterly earnings of $2.01 per share in its upcoming release, pointing to a year-over-year increase of 43.6%. It is anticipated that revenues will amount to $15.34 billion, exhibiting an increase of 5.9% compared to the year-ago quarter. Over the last 30 days, there has been an upward revision of 7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts'' collective reconsideration of their initial forecasts over the course of this timeframe. Ahead of a company''s earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock. While investors typically … Full story available on Benzinga.

Here’s Why Merck & Co. (MRK) Outperformed in Q1
Apr 23, 2024 11:49am

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]

Source:Insider Monkey
Cramers week ahead: Earnings from Tesla, Merck and Big Tech
Apr 19, 2024 23:33pm

CNBC''sJim Cramersaid next week''s PCE index report will be the real gauge of inflation.

Merck garners Canadian approval for Keytruda in first-line gastroesophageal cancer
Apr 19, 2024 16:03pm

Health Canada approves Merck''s Keytruda as first-line therapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma. Read more here.

Source:Seeking Alpha
Health Canada Approves Merck''s Keytruda Plus Chemotherapy To Treat Gastric Cancers
Apr 19, 2024 12:00pm

KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) on Friday said its Keytruda in combination with fluoropyrimidine- and platinum-containing-chemotherapy has been approved by Health Canada for the …

Source:Finanz Nachrichten
Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To
Apr 17, 2024 19:52pm

No summary available.

Source:Seeking Alpha